NeuroOne Announces CFO Succession Plan as Ron McClurg Retires

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced on April 30, 2026, that Chief Financial Officer Ron McClurg will retire effective June 30, 2026, after more than five years of service. McClurg will remain with the company as a Senior Advisor through December 31, 2026, to facilitate a smooth transition. Chris Volker, currently the Chief Operating Officer, will assume the permanent CFO role, while newly appointed Chief Business Officer David Wambeke will take over many of Volker's previous responsibilities.

Dave Rosa, CEO of NeuroOne, expressed gratitude for McClurg's contributions, stating, "Ron's retirement marks the culmination of a long and successful career, and we are grateful for his leadership, stewardship, and commitment to NeuroOne." Rosa also welcomed Volker's appointment, noting his deep leadership experience across medtech, finance, strategy, and commercial operations. "I believe he is the right person to step into this role as we continue advancing NeuroOne’s technologies and growth strategy," Rosa added.

McClurg commented on his tenure, saying, "It has been a privilege to serve as NeuroOne’s Chief Financial Officer for over five years and to work alongside such a talented team. I am proud of this team and the benefits our products are providing for patients." Volker expressed honor in taking on the CFO role, emphasizing the company's momentum in product pipeline and commercial growth.

Volker brings over 25 years of operational and financial leadership in the medical device industry, including senior roles at Abbott, Cardiovascular Systems, Inc. (CSI), and St. Jude Medical. At CSI, he served as Vice President & General Manager of International, overseeing international P&L and commercial expansion. He began his career in healthcare and technology investment banking at Dain Rauscher. Volker holds an MBA from The Wharton School and is a CFA charterholder.

The succession plan is critical for NeuroOne as it continues to advance its electrode technology platform and explore new applications such as drug delivery, basivertebral nerve ablation, and spinal cord stimulation. The company's FDA-cleared products, including Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System, and OneRF Trigeminal Nerve Ablation System, are designed to improve surgical outcomes for neurological disorders. For more information, visit nmtc1.com.

This transition ensures continuity in financial leadership as NeuroOne pursues its strategic objectives. The company's forward-looking statements highlight risks and uncertainties, but the management change is expected to support ongoing growth. The original press release is available on NewMediaWire.